Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 3:13:824926.
doi: 10.3389/fneur.2022.824926. eCollection 2022.

Therapeutic Advances in Multiple Sclerosis

Jennifer H Yang  1 , Torge Rempe  2 , Natalie Whitmire  1 , Anastasie Dunn-Pirio  1 , Jennifer S Graves  1
Affiliations
Review

Therapeutic Advances in Multiple Sclerosis

Jennifer H Yang et al. Front Neurol. .

Abstract

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes significant disability and healthcare burden. The treatment of MS has evolved over the past three decades with development of new, high efficacy disease modifying therapies targeting various mechanisms including immune modulation, immune cell suppression or depletion and enhanced immune cell sequestration. Emerging therapies include CNS-penetrant Bruton's tyrosine kinase inhibitors and autologous hematopoietic stem cell transplantation as well as therapies aimed at remyelination or neuroprotection. Therapy development for progressive MS has been more challenging with limited efficacy of current approved agents for inactive disease and older patients with MS. The aim of this review is to provide a broad overview of the current therapeutic landscape for MS.

Keywords: demyelination; disease modifying therapy; multiple sclerosis; neurodegeneration; review.

PubMed Disclaimer

Conflict of interest statement

JY has received speaker fees for NeurologyLive. TR received grant funding from the National Multiple Sclerosis Society. JG has received grant or contract funding from Biogen, Octave, Novartis, and EMD-Serono and has served on advisory boards for Bayer and Genentech and has received speaker fees from BMS and Alexion. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
DMT mechanism of action.
See this image and copyright information in PMC

References

    1. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. (2019) 92:e1029–40. 10.1212/WNL.0000000000007035 - DOI - PMC - PubMed
    1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. (2017) 16:877–897. 10.1016/S1474-4422(17)30299-5 - DOI - PMC - PubMed
    1. Ascherio A, Munger KL. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin Neurol. (2016) 36:103–14. 10.1055/s-0036-1579693 - DOI - PubMed
    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. (2018) 378:169–80. 10.1056/NEJMra1401483 - DOI - PMC - PubMed
    1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. (2018) 17:162–73. 10.1016/S1474-4422(17)30470-2 - DOI - PubMed